|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15421543154415451546154715481549155015511552...15771578» |
- ||| Sutent (sunitinib) / Pfizer
Trial completion, Enrollment change: A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=227, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed | N=300 --> 227
- Trial primary completion date: Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors (clinicaltrials.gov) - Oct 15, 2014
P=N/A, N=30, Recruiting, Sponsor: University of Iowa
Active, not recruiting --> Completed | N=300 --> 227 Trial primary completion date: Jul 2014 --> Jul 2015
- Trial primary completion date: Proton Radiation for Chordomas and Chondrosarcomas (clinicaltrials.gov) - Oct 15, 2014
P1/2, N=50, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Trial primary completion date: Jul 2014 --> Jul 2015 Trial primary completion date: Mar 2014 --> Mar 2015
- Trial completion, Trial primary completion date: Proton Radiotherapy for Extremity Soft Tissue Sarcoma (clinicaltrials.gov) - Oct 15, 2014
P2, N=124, Completed, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Trial primary completion date: Mar 2014 --> Mar 2015 Recruiting --> Completed | Trial primary completion date: Jun 2017 --> May 2014
- | Enrollment open: Evaluation of Technetium Tc 99m Tilmanocept (Lymphoseek®) Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT and SPECT/CT Imaging (clinicaltrials.gov) - Oct 11, 2014
P2, N=12, Recruiting, Sponsor: Navidea Biopharmaceuticals
Recruiting --> Completed | Trial primary completion date: Jun 2017 --> May 2014 Not yet recruiting --> Recruiting
- Biomarker, Enrollment change: 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy (clinicaltrials.gov) - Oct 11, 2014
P1/2, N=150, Recruiting, Sponsor: Sanjiv Sam Gambhir
Not yet recruiting --> Recruiting N=100 --> 150
- || imatinib / Generic mfg.
New P3 trial, Stroma: ImadGist: Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (clinicaltrials.gov) - Oct 11, 2014
P3, N=256, Not yet recruiting, Sponsor: Centre Leon Berard
- ||||| Truseltiq (infigratinib) / BridgeBio, Pfizer, Xediton Pharma
New P1/2 trial, Combination therapy, Stroma, Metastases: BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) (clinicaltrials.gov) - Oct 11, 2014
P1/2, N=62, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- |||| Truseltiq (infigratinib) / BridgeBio, Pfizer, Xediton Pharma
Enrollment open, Combination therapy, Stroma, Metastases: BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) (clinicaltrials.gov) - Oct 11, 2014
P1/2, N=62, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
N=100 --> 150 Not yet recruiting --> Recruiting
- Votrient (pazopanib) / Novartis, BeiGene
Enrollment open, Trial initiation date, Metastases: GEIS-32: Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma (clinicaltrials.gov) - Oct 11, 2014
P2, N=70, Recruiting, Sponsor: Grupo Espanol de Investigacion en Sarcomas
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Mar 2014 --> Jun 2014
- ||||||| Tasigna (nilotinib) / Novartis, Inhibikase
Trial completion, Trial primary completion date, Stroma: Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib. (clinicaltrials.gov) - Oct 11, 2014
P3, N=125, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Initiation date: Mar 2014 --> Jun 2014 Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Jul 2014
- | Trial completion, Trial primary completion date: GIST-RT: Radiation Therapy as Palliative Treatment of GIST (clinicaltrials.gov) - Oct 11, 2014
P1/2, N=25, Completed, Sponsor: Heikki Joensuu
Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Jul 2014 Recruiting --> Completed | Trial primary completion date: Jun 2012 --> Feb 2014
- || Odomzo (sonidegib) / Sun Pharma
Trial primary completion date: A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB (clinicaltrials.gov) - Oct 10, 2014
P1/2, N=76, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | Trial primary completion date: Jun 2012 --> Feb 2014 Trial primary completion date: Aug 2014 --> Feb 2015
- | bendamustine / Generic mfg.
Trial suspension: Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma (clinicaltrials.gov) - Oct 10, 2014
P2, N=61, Suspended, Sponsor: University of Washington
Trial primary completion date: Aug 2014 --> Feb 2015 Recruiting --> Suspended
- Sutent (sunitinib) / Pfizer
Phase classification, Stroma, Metastases: A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor (clinicaltrials.gov) - Oct 10, 2014
P2, N=30, Recruiting, Sponsor: Pfizer
Recruiting --> Suspended Phase classification: P1/2 --> P2
- New P2 trial: Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation (clinicaltrials.gov) - Oct 10, 2014
P2, N=18, Not yet recruiting, Sponsor: St. Jude Children's Research Hospital
- leucovorin calcium / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date, Combination therapy: Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas (clinicaltrials.gov) - Oct 10, 2014
P1, N=39, Recruiting, Sponsor: City of Hope Medical Center
Phase classification: P1/2 --> P2 Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Oct 2014 | Trial primary completion date: Apr 2019 --> Oct 2018
- || Talzenna (talazoparib) / Pfizer
Enrollment closed, Metastases: Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors (clinicaltrials.gov) - Oct 10, 2014
P1, N=85, Active, not recruiting, Sponsor: BioMarin Pharmaceutical
Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Oct 2014 | Trial primary completion date: Apr 2019 --> Oct 2018 Recruiting --> Active, not recruiting
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Enrollment closed, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Oct 10, 2014
P1b, N=120, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Inlyta (axitinib) / Pfizer, Torisel (temsirolimus) / Pfizer, Sutent (sunitinib) / Pfizer
Phase classification, Trial initiation date, Stroma, Metastases: Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR] (clinicaltrials.gov) - Oct 4, 2014
P4, N=1600, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Phase classification: P=N/A --> P4 | Initiation date: Feb 2008 --> Jan 2013
- Modufolin (arfolitixorin) / Isofol Medical, Solasia
Enrollment open, Trial primary completion date: Investigation of [6R] 5,10-methylenetetrahydrofolate (Arfolitixorin) as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX. (clinicaltrials.gov) - Oct 4, 2014
P1/2, N=6, Recruiting, Sponsor: Isofol Medical AB
Phase classification: P=N/A --> P4 | Initiation date: Feb 2008 --> Jan 2013 Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2014 --> Jul 2015
- trebananib (AMG 386) / Amgen
Enrollment change, Surgery, Metastases: Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Oct 2, 2014
P2, N=16, Suspended, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2014 --> Jul 2015 N=41 --> 16
- | evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
New P2 trial, Combination therapy, Metastases: EMR200592-008: A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Oct 2, 2014
P2, N=46, Recruiting, Sponsor: Merck KGaA
- Ibrance (palbociclib) / Pfizer
New P1 trial: Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors (clinicaltrials.gov) - Oct 2, 2014
P1, N=40, Not yet recruiting, Sponsor: Pediatric Brain Tumor Consortium
- Trial completion, Enrollment change, Trial primary completion date, Surgery: Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass (clinicaltrials.gov) - Oct 2, 2014
P=N/A, N=21, Completed, Sponsor: M.D. Anderson Cancer Center
N=41 --> 16 Active, not recruiting --> Completed | N=30 --> 21 | Trial primary completion date: Mar 2015 --> Mar 2014
- | Avastin (bevacizumab) / Roche
Enrollment open, Combination therapy: SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors (clinicaltrials.gov) - Sep 30, 2014
P2, N=25, Recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
Active, not recruiting --> Completed | N=30 --> 21 | Trial primary completion date: Mar 2015 --> Mar 2014 Active, not recruiting --> Recruiting
- ||| Trial completion, Trial primary completion date, Biopsy: Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=140, Completed, Sponsor: Northwestern University
Active, not recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Jul 2014 --> Feb 2014
- Trial primary completion date: Proton Radiation Therapy for Spinal Tumors (clinicaltrials.gov) - Sep 28, 2014
P2, N=34, Recruiting, Sponsor: University of Florida
Recruiting --> Completed | Trial primary completion date: Jul 2014 --> Feb 2014 Trial primary completion date: May 2024 --> May 2025
- sildenafil / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial primary completion date: Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers (clinicaltrials.gov) - Sep 28, 2014
P1, N=50, Suspended, Sponsor: Virginia Commonwealth University
Trial primary completion date: May 2024 --> May 2025 Trial primary completion date: Aug 2014 --> Aug 2016
- Votrient (pazopanib) / Novartis, BeiGene
Trial primary completion date, Metastases: Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma (clinicaltrials.gov) - Sep 28, 2014
P2, N=47, Recruiting, Sponsor: ACORN Research, LLC
Trial primary completion date: Aug 2014 --> Aug 2016 Trial primary completion date: Jun 2014 --> Jun 2015
- irinotecan / Generic mfg., docetaxel / Generic mfg.
Trial primary completion date: Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas. (clinicaltrials.gov) - Sep 28, 2014
P2, N=35, Recruiting, Sponsor: National Cancer Center, Korea
Trial primary completion date: Jun 2014 --> Jun 2015 Trial primary completion date: Dec 2013 --> Sep 2014
- SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax, Roswell Park Comprehensive Cancer Center
Trial primary completion date: Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma (clinicaltrials.gov) - Sep 28, 2014
P1, N=9, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Dec 2013 --> Sep 2014 Trial primary completion date: Sep 2014 --> May 2014
- | Trial suspension, Trial primary completion date, Metastases: Study of 124I-NM404 in Advanced Solid Malignancies (clinicaltrials.gov) - Sep 28, 2014
P1/2, N=108, Suspended, Sponsor: University of Wisconsin, Madison
Trial primary completion date: Sep 2014 --> May 2014 Recruiting --> Suspended | Trial primary completion date: Dec 2014 --> Jul 2016
- bortezomib / Generic mfg.
Phase classification: Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma (clinicaltrials.gov) - Sep 28, 2014
P1, N=24, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended | Trial primary completion date: Dec 2014 --> Jul 2016 Phase classification: P=N/A --> P1
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Phase classification, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Sep 28, 2014
P1, N=43, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Phase classification: P=N/A --> P1 Phase classification: P1/2 --> P1
- | efatutazone (CS-7017) / Daiichi Sankyo
New P2 trial, Surgery: Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Sep 28, 2014
P2, N=36, Not yet recruiting, Sponsor: Alliance for Clinical Trials in Oncology
- ||||| Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
New P2 trial, Metastases: TAUL: Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma (clinicaltrials.gov) - Sep 28, 2014
P2, N=150, Recruiting, Sponsor: Mario Negri Institute for Pharmacological Research
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
New P2 trial, Metastases: TRAVELL: Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma (clinicaltrials.gov) - Sep 28, 2014
P2, N=95, Recruiting, Sponsor: Italian Sarcoma Group
- ||| dovitinib (TKI258) / Novartis, Oncoheroes
Enrollment closed: Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma (clinicaltrials.gov) - Sep 28, 2014
P2, N=55, Active, not recruiting, Sponsor: Manmeet Ahluwalia, MD
Phase classification: P1/2 --> P1 Recruiting --> Active, not recruiting
- ||||| Rintega (rindopepimut) / Celldex
Enrollment closed: Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Sep 28, 2014
P3, N=700, Active, not recruiting, Sponsor: Celldex Therapeutics
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Trial completion: Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors (clinicaltrials.gov) - Sep 28, 2014
P2, N=50, Completed, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | vinblastine / Generic mfg., celecoxib oral / Generic mfg.
Trial completion, Combination therapy, Metastases: Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors (clinicaltrials.gov) - Sep 28, 2014
P2, N=38, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Koselugo (selumetinib) / Merck (MSD), AstraZeneca
Enrollment change, Trial primary completion date, Combination therapy: SCART: A Study of Selumetinib in Patients With Kaposi's Sarcoma (clinicaltrials.gov) - Sep 22, 2014
P1/2, N=29, Recruiting, Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
Active, not recruiting --> Completed N=37 --> 29 | Trial primary completion date: Jun 2014 --> Jun 2015
- Clinical: EUS-FNA: A Clinical Trial With a New Needle Device Comparing Two Needles for EUS_FNA of Solid Lesions. (clinicaltrials.gov) - Sep 22, 2014
P=N/A, N=144, Recruiting, Sponsor: Istituto Clinico Humanitas
- Trial primary completion date: NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) (clinicaltrials.gov) - Sep 22, 2014
P1/2, N=15, Active, not recruiting, Sponsor: University Hospital, Basel, Switzerland
N=37 --> 29 | Trial primary completion date: Jun 2014 --> Jun 2015 Trial primary completion date: Dec 2013 --> Mar 2015
- Biomarker, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Sep 22, 2014
P2, N=800, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
Trial primary completion date: Dec 2013 --> Mar 2015 Trial primary completion date: Feb 2014 --> Sep 2015
- | Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Trial completion, Enrollment change, Trial primary completion date, Combination therapy: Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma (clinicaltrials.gov) - Sep 22, 2014
P1, N=26, Completed, Sponsor: Exelixis
Trial primary completion date: Feb 2014 --> Sep 2015 Active, not recruiting --> Completed | N=85 --> 26 | Trial primary completion date: Apr 2013 --> Nov 2012
- | Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Cabometyx (cabozantinib tablet) / Exelixis
New P2 trial: Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma (clinicaltrials.gov) - Sep 19, 2014
P2, N=85, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- ||||| Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Enrollment change: An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS) (clinicaltrials.gov) - Sep 16, 2014
P3, N=121, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Active, not recruiting --> Completed | N=85 --> 26 | Trial primary completion date: Apr 2013 --> Nov 2012 N=80 --> 121
- | Votrient (pazopanib) / Novartis, BeiGene
Enrollment closed, Metastases: Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma (clinicaltrials.gov) - Sep 16, 2014
P2, N=38, Active, not recruiting, Sponsor: ACORN Research, LLC
N=80 --> 121 Recruiting --> Active, not recruiting